Key Takeaways
- • Renaissance Technologies LLC opened a new $247.8M position in Medtronic ($MDT) based on SEC 13F filings for the second quarter of 2026 (ending June 30, 2026).
- • Medtronic experienced significant institutional portfolio rotation in Q2 2026, with 960 institutional investors adding shares while 1,300 reduced their positions, indicating mixed market sentiment.
- • Capital Research Global Investors executed the largest reduction, divesting 28.7M shares (-68.4%) valued at approximately $2.24B; JPMorgan Chase simultaneously added 27.8M shares (+inf%) worth approximately $2.17B.
- • Additional notable institutional activity included UBS AM's 93.6% position reduction (9.1M shares, $712M value) and Wellington Management Group's 43.7% cut in Q1 2026 (5.8M shares, $505M value), signaling cautious sentiment among major asset managers.
- • The broader $MDT institutional holder landscape shows active rebalancing, with SG Americas Securities and JPMorgan Chase among the few major players increasing exposure during the quarter.
Summary
Renaissance Technologies LLC, the quantitative investment firm, initiated a new $247.8 million position in Medtronic ($MDT) during the second quarter of 2026, according to regulatory filings disclosed on August 13, 2026. The position was revealed through the fund's most recent SEC 13F filing, which captures institutional equity holdings as of June 30, 2026.
The timing of Renaissance's entry into $MDT coincides with substantial portfolio reshuffling among institutional investors. During Q2 2026, the aggregate institutional investor base showed divergent views on Medtronic: 960 institutions increased their holdings while 1,300 reduced positions, underscoring the stock's polarizing valuation or fundamental outlook among sophisticated investors.
The most consequential moves came from established asset managers. Capital Research Global Investors executed a dramatic exit, liquidating 28.7 million shares—a 68.4% reduction representing approximately $2.24 billion in market value. This divestment was largely offset by JPMorgan Chase's aggressive accumulation of 27.8 million shares valued near $2.17 billion, suggesting institutional disagreement on $MDT's near-term trajectory. UBS Asset Management Americas followed with a substantial 93.6% position reduction (9.1 million shares, $712 million), while Capital World Investors trimmed 8.1 million shares (-49.3%, $636 million). Wellington Management Group cut its stake by 43.7% in the prior quarter (Q1 2026), offloading 5.8 million shares valued at $505 million.
Counterbalancing these exits, SG Americas Securities added 6.5 million shares worth approximately $509 million, and JPMorgan's acquisition represented one of the few major institutional accumulations during the period. The composite picture reflects typical portfolio rebalancing dynamics typical of mid-year institutional repositioning, with some managers trimming healthcare or medical device exposure while others, like Renaissance and JPMorgan, saw relative value opportunities in $MDT's valuation.
The timing of Renaissance's entry into $MDT coincides with substantial portfolio reshuffling among institutional investors. During Q2 2026, the aggregate institutional investor base showed divergent views on Medtronic: 960 institutions increased their holdings while 1,300 reduced positions, underscoring the stock's polarizing valuation or fundamental outlook among sophisticated investors.
The most consequential moves came from established asset managers. Capital Research Global Investors executed a dramatic exit, liquidating 28.7 million shares—a 68.4% reduction representing approximately $2.24 billion in market value. This divestment was largely offset by JPMorgan Chase's aggressive accumulation of 27.8 million shares valued near $2.17 billion, suggesting institutional disagreement on $MDT's near-term trajectory. UBS Asset Management Americas followed with a substantial 93.6% position reduction (9.1 million shares, $712 million), while Capital World Investors trimmed 8.1 million shares (-49.3%, $636 million). Wellington Management Group cut its stake by 43.7% in the prior quarter (Q1 2026), offloading 5.8 million shares valued at $505 million.
Counterbalancing these exits, SG Americas Securities added 6.5 million shares worth approximately $509 million, and JPMorgan's acquisition represented one of the few major institutional accumulations during the period. The composite picture reflects typical portfolio rebalancing dynamics typical of mid-year institutional repositioning, with some managers trimming healthcare or medical device exposure while others, like Renaissance and JPMorgan, saw relative value opportunities in $MDT's valuation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.